Accueil   Diary - News   All news Adocia to Present New Clinical Data on BioChaperone® Technology

Adocia to Present New Clinical Data on BioChaperone® Technology

Lyon, France February 12th, 2019 – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of approved proteins, today announced that four abstracts featuring its BioChaperone® technology have been accepted for presentation at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019) being held February 20-23, 2019 in Berlin, Germany.


Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree